After being approved as a supplier to some of the world’s largest pharma companies, Medicollect is proud of also having completed vendor qualification in one of the largest CROs, Medpace.
Medpace has operations in over 50 countries and holds a strong position in diabetes trials. Therefore Medicollect and Medpace match exceptionally well.
Medpace has already asked Medicollect to provide participants for a study on the treatment of diabetic foot ulcers in both the UK and Denmark. We expect a lot from the cooperation with Medpace “says Torben Lind, CEO of Medicollect.